Metastatic adamantinoma responds to treatment with receptor tyrosine kinase inhibitor

Adamantinoma is a rare tumor that affects long bones, and it is estimated to account for 0.1 to 0.5% of all primary bone tumors [1]. It is named for its histological similarity to the tumor of the ...